part of its European HIV prevention work, NAM is collaborating with AVAC to provide
a series of webinars (conference calls with accompanying slides) to train and
inform prevention advocates and anyone interested in the newest developments in
HIV prevention technology.
second webinar is entitled:
Microbicides research in Europe
Click here to register for the webinar and get phone numbers and joining
90-minute webinar will examine the current state of research into topical
microbicides – gels, lubes and devices that can be used to prevent HIV
transmission during sex. It will provide advocates with an overview of global
and European topical microbicide research. The presentations will be followed
by a question and answer session with our expert speakers. The webinar will be
conducted in English.
and date: 2pm UK
time (GMT), Tuesday 26 February (3pm CET)
webinar will feature presentations by:
- Dr Sheena
McCormack – Overview of topical microbicide research. Dr
Sheena McCormack is Senior Clinical Scientist at the Clinical Trials Unit of
the UK Medical Research Council. She is Principal Investigator of the Microbicides
Development Programme, which ran the MDP
301 Phase III microbicide trial in four countries in
sub-Saharan Africa, and of the recently started PROUD trial of Truvada pre-exposure prophylaxis in UK gay men.
- Dr Charles Kelly – Outstanding research from the CHAARM microbicides
research consortium. Dr
Charles Kelly of King’s College, London
is co-ordinator of the Combined Highly Active Anti-Retroviral Microbicides
(CHAARM) programme, a collaborative project co-funded by the European Union
under the 7th Framework Programme (FP7) for Research and Technological
Development. CHAARM is a consortium of 31 partners representing 9 different
countries in Europe including Ukraine,
as well as South Africa and
with a €12m budget.
Jeremy Nuttall – Update on IPM’s
pipeline: the dapivirine ring and beyond. Jeremy Nuttall is the
Senior Director of Preclinical Sciences and Product Development for the
International Partnership for Microbicides (IPM), where he is responsible for
the preclinical testing of candidate microbicides and has broader product
development responsibilities. Jeremy joined IPM in 2003 and has over 25
years of experience in drug development. Prior to IPM he worked as a
toxicologist in contract research organisations and spent over 8 years in
regulatory affairs at GlaxoSmithKline.
- Harriet Langanke – Community
advocacy for microbicides in Europe. Harriet
Langanke is founder and director of GSSG: Gemeinnützige Stiftung Sexualität und
Gesundheit, the German Foundation on sexuality and health. She is a journalist
who has worked in the field of HIV and sexual health since 1991; she is also one of
the co-founders of Germany’s
national network Women and AIDS which celebrated its 20th
anniversary last year. As an expert for HIV and STI prevention she works
primarily for and with women.
discussion will be introduced and moderated by Gus Cairns. Gus is a writer at NAM, where he
edits HIV treatment update and Preventing HIV. He also
edits the HIV prevention news: Europe bulletin
as part of NAM’s
programme of European prevention advocacy. He is a member of the European AIDS
Treatment Group, co-chair of the Steering Committee of the PROUD PrEP trial,
and a member of the steering committee of the Global Forum for MSM and HIV.
advocates interested in learning more about microbicides research
are encouraged to join this webinar and to email questions in advance to firstname.lastname@example.org. During
the event, participants will be encouraged to ask questions via telephone.
To register for the webinar and get phone numbers and joining
instructions: click this link
The following webinar, scheduled for 26 March, will examine
the latest data on HIV treatment as prevention.
This project has been supported via a
grant from Gilead Sciences Europe Ltd.
Gilead Sciences Europe Ltd has
provided funding for this project and has had no editorial control over the
content of the materials.